Key result
MeRes100 bioresorbable scaffold shows low systemic exposure with peak sirolimus levels of ~7.5 ng/mL.
Why the study?
The systemic release profile of sirolimus from the novel MeRes100 bioresorbable vascular scaffold implanted for de novo native coronary artery lesions was not previously evaluated.
Answers are grounded in this paper and cite their sources.
The MeRes100 sirolimus-eluting bioresorbable vascular scaffold demonstrates a predictable pharmacokinetic profile with limited systemic exposure, supporting its safety.
Background: MeRes 100™ (Meril Life Sciences Pvt. Ltd., Vapi, India) is a novel sirolimus-eluting bioresorbable vascular scaffold (BRS). The purpose of this sub-study of MeRes-1 trial is to evaluate the systemic release of sirolimus from MeRes100 BRS implanted for the treatment of de novo native coronary artery lesions. Methods: The MeRes-1 is a prospective, multicenter, first-in-human trial of sirolimus-eluting MeRes100 BRS. The pharmacokinetic sub-study was conducted at two Indian sites in 10 patients who were implanted with the MeRes100 BRS loaded with sirolimus at a dose of 1.25 µg/mm 2 . Venous blood samples were collected at pre-dose and 12-time points after implantation of the scaffold. Sirolimus concentration was successively analyzed using ultra-performance liquid chromatography-electrospray ionization tandem mass spectrometry method. Results: A total of 12 scaffolds were implanted in 10 patients. Non-compartmental analysis demonstrated time to reach peak concentration of sirolimus between 0.5 h to 3 h after scaffold implantation. The peak concentration (C max ) was deduced to be 7.47 ± 2.61 ng/mL, AUC was 436.45 ± 171.24 h·ng/mL, and the t ½ was observed at 98.59 ± 33.58 h. The clearance was 0.66 ± 0.16 L/h and lower limit of quantification was detectable at 14.1 days. Conclusions: The MeRes-1 pharmacokinetic sub-study confirmed that MeRes100 BRS is safe and tolerable at limited systemic exposure of sirolimus. Cardiol Res. 2018;9(6):364-369 doi: https://doi.org/10.14740/cr799 Â
No takes yet. Share an insight, caveat, or question.
Chandra et al. (2018) studied De novo native coronary artery lesions (n=10). MeRes100 sirolimus-eluting bioresorbable vascular scaffold was evaluated on Peak concentration (Cmax) of sirolimus. The MeRes100 bioresorbable vascular scaffold demonstrated a mean peak sirolimus concentration of 7.47 ng/mL, confirming limited systemic exposure and a safe pharmacokinetic profile.
Synapse has enriched 10 related papers. Consider them for comparative context: